GlobeNewsWire
25 Aug 2026, 22:36 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy. — A negative advisory committee vote on a primary drug candidate significantly reduces the probability of FDA approval and future revenue.
-0.90The FDA determined that Capricor's statistical analysis plan changes were post-hoc and exploratory, rendering the benefit-risk assessment for deramiocel unfavorable. — The FDA's rejection of the company's data analysis methodology suggests fundamental flaws in the clinical trial reporting.
-0.80A class action lawsuit has been filed against Capricor Therapeutics alleging securities fraud and unlawful business practices. — Litigation creates additional financial liabilities and management distraction, though it is secondary to the drug's clinical failure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit following a massive stock price collapse due to FDA rejection and allegations of securities fraud.
The company is being investigated by a law firm for potential claims on behalf of investors.
The company is being investigated by a law firm for potential claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
